GlassScriptPhysician profile
Scott E Zeilstra
NPI 1174963490
$8,000.72
in general payments reported to CMS, 2019-2025
33 companies · $2,587 in 2025
The $2,587 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $629 · 2023: $1,821 · 2024: $2,654 · 2025: $2,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,883 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,883.09 |
| Education | $178.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,887.66 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $939.68 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $589.90 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $464.50 | 2021-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $429.12 | 2024-2025 | Vowst, Zenpep |
| Gilead Sciences, INC. | $406.56 | 2021-2025 | |
| Lilly USA, LLC | $384.09 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $346.41 | 2021-2025 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $342.73 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $341.82 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $272.43 | 2022-2025 | Ibsrela |
| Pfizer INC. | $192.02 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $157.62 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $127.77 | 2022-2025 | Linzess |
| Ipsen Biopharmaceuticals, INC | $122.75 | 2024-2025 | Iqirvo, Bylvay |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $102.54 | 2023-2024 | Zeposia |
| Celltrion USA INC. | $101.09 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Enterra Medical, INC. | $84.25 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $81.61 | 2022-2023 | Dificid |
| Madrigal Pharmaceuticals | $81.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $77.89 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $69.29 | 2022-2023 | |
| Organon LLC | $66.32 | 2023-2025 | Renflexis, Hadlima |
| Ferring Pharmaceuticals INC. | $62.74 | 2023-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $46.75 | 2023-2025 | Voquezna |
| Daiichi Sankyo INC. | $42.11 | 2023-2025 | Injectafer |
| Amgen INC. | $42.02 | 2023 | Amjevita, Avsola |
| Astrazeneca Pharmaceuticals LP | $28.05 | 2024 | |
| Janssen Pharmaceuticals, INC | $25.09 | 2023-2025 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.35 | 2023 | Cyltezo |
| Novo Nordisk INC | $22.46 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $21.58 | 2023 | Givlaari |
| Axonics, INC. | $17.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Zeilstra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.